- United States
- /
- Biotech
- /
- NasdaqGS:NTRA
Natera Full Year 2024 Earnings: Beats Expectations
Natera (NASDAQ:NTRA) Full Year 2024 Results
Key Financial Results
- Revenue: US$1.70b (up 57% from FY 2023).
- Net loss: US$190.4m (loss narrowed by 56% from FY 2023).
- US$1.53 loss per share (improved from US$3.78 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Natera Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 9.6% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Natera you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:NTRA
Natera
A diagnostics company, provides molecular testing services worldwide.
Flawless balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Weekly Picks

Looking to be second time lucky with a game-changing new product
PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Inotiv NAMs Test Center
This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti
Recently Updated Narratives

Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.

Beyond the "Value Trap"—Defending the $50 Intrinsic Floor

The "Geopolitical Discount" vs. The Monopolistic Floor: The Two Narratives of TSM
Popular Narratives

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

The "Physical AI" Monopoly – A New Industrial Revolution
